Repairing Cells and Longevity Myths with Dr. Charles Brenner

Repairing Cells and Longevity Myths with Dr. Charles Brenner

Charles Brenner, a leading biochemist at City of Hope National Medical Center in L.A., discovered a vitamin precursor called NR that seems to enable repair of cellular damage that happens as we get older.

Charles Brenner

Meet Charles Brenner, the Longevity Skeptic. Brenner, a leading biochemist at City of Hope National Medical Center in L.A., has been attending the largest longevity conferences with one main purpose: to point out that some of the other speakers are full of it.

Brenner is "throwing cold water" on several scientists in the field of aging, accusing them of hyping various fountains of youth, despite limited evidence for these therapies.

In this podcast episode, Brenner sat down with Leaps.org to discuss his groundbreaking work on metabolism and his efforts to counter what he considers to be bad science.




Listen on Apple | Listen on Spotify | Listen on Stitcher | Listen on Amazon | Listen on Google


In addition to bringing his candor to conferences, Brenner is applying it in academic journals, publishing a paper in September, "A Science-Based Review of the World's Best-Selling Book on Aging," in which he pans the author of this bestseller, David Sinclair, a Harvard biologist, for talking up the potential for humans to live far past 100. These aspirations may sound nice, but they're not backed by science, Brenner says. He's had high-profile debates online with Sinclair and Aubrey de Grey, a prominent biomedical gerontologist.

Meanwhile, in his own lab work, Brenner is credited with identifying a vitamin precursor called NR that seems to enable repair of cellular damage that happens as we get older - a major discovery that he's helped turn into a supplement, commercialized with a company called ChromaDex.

Whether it's possible to extend human lifespan is a pressing question as investments in longevity startups are projected to increase from $40 billion to $600 billion over the next three years. The field of biological aging seems split on the question of whether "anti-aging" therapies can significantly lengthen our natural lifespans, as Sinclair believes. Brenner, Morgan Levine of Altos Labs and Matt Kaeberlein of the University of Washington have argued that the only realistic goal is to extend one's window of healthy years, or healthspan, rather than trying to break the biological ceiling of our species.

Brenner is an intriguing figure in these debates. Although he’s been introduced in public appearances as a longevity skeptic, he calls himself an optimist.

Links:
Charles Brenner, City of Hope

Charles Brenner Lab

Charles Brenner on Twitter

Charles Brenner's debate with Aubrey de Grey

Brenner's paper, "A Science-Based Review of the World's Best-Selling Book on Aging"

Peter Attia's recent blog on NR supplements

Brad Stanfield's recent reaction to "David Sinclair vs Charles Brenner"

ChromaDex NR supplement

Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.
Your phone could show if a bridge is about to collapse

Researchers have tested a new smartphone app that could gather data about whether bridges are "structurally deficient" —a low-cost citizen-scientist alternative to current methods that are expensive and complex.

Adobe Stock

In summer 2017, Thomas Matarazzo, then a postdoctoral researcher at the Massachusetts Institute of Technology, landed in San Francisco with a colleague. They rented two cars, drove up to the Golden Gate bridge, timing it to the city’s rush hour, and rode over to the other side in heavy traffic. Once they reached the other end, they turned around and did it again. And again. And again.

“I drove over that bridge 100 times over five days, back and forth,” says Matarazzo, now an associate director of High-Performance Computing in the Center for Innovation in Engineering at the United States Military Academy, West Point. “It was surprisingly stressful, I never anticipated that. I had to maintain the speed of about 30 miles an hour when the speed limit is 45. I felt bad for everybody behind me.”

Keep Reading Keep Reading
Lina Zeldovich

Lina Zeldovich has written about science, medicine and technology for Popular Science, Smithsonian, National Geographic, Scientific American, Reader’s Digest, the New York Times and other major national and international publications. A Columbia J-School alumna, she has won several awards for her stories, including the ASJA Crisis Coverage Award for Covid reporting, and has been a contributing editor at Nautilus Magazine. In 2021, Zeldovich released her first book, The Other Dark Matter, published by the University of Chicago Press, about the science and business of turning waste into wealth and health. You can find her on http://linazeldovich.com/ and @linazeldovich.

The Friday Five: Sugar could help catch cancer early

In this week's Friday Five, catching cancer early could depend on sugar, how to boost memory in a flash, a tiny sandwich cake could help the heart, and meet the top banana in the fight against Covid.

Adobe Stock

The Friday Five covers five stories in research that you may have missed this week. There are plenty of controversies and troubling ethical issues in science – and we get into many of them in our online magazine – but this news roundup focuses on scientific creativity and progress to give you a therapeutic dose of inspiration headed into the weekend.

Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.